Anakinra

Anakinra is recombinant human interleukin-1 receptor antagonist produced in E. coli, differing from the native protein by a single added N-terminal methionine and the absence of glycosylation. It binds IL-1 receptor type 1 with affinity comparable to IL-1 itself but fails to recruit the IL-1 receptor accessory protein, so no signal is transduced - it is a pure competitive block rather than a partial agonist. Because it blocks the receptor rather than a single cytokine, it neutralises both IL-1 alpha and IL-1 beta, which is why it works in conditions where inflammasome-driven IL-1 beta is the dominant driver: cryopyrin-associated periodic syndromes, adult-onset Still's disease, systemic JIA, gout flares and pericarditis. Its very short half-life is both a weakness (daily injections) and a practical strength - if a serious infection develops, the block washes out within a day.

Targets: IL-1 receptor type 1, IL-1 alpha, IL-1 beta, Inflammasome downstream signalling

• · 100 mg daily is the standard adult dose, supplied in prefilled graduated syringes. Reduce to every other day if creatinine clearance is below 30 mL/min.
• · Weight-based paediatric dosing runs 1-2 mg/kg/day and can be escalated to 4 mg/kg/day (up to 8 mg/kg in macrophage activation syndrome) under specialist care.

Work out your exact syringe units →

• very commonInjection-site reaction— Affects the majority of users in the first month - red, itchy, sometimes painful welts that usually diminish with continued use.
• commonHeadache
• uncommonSerious infection— Blocking IL-1 blunts the febrile response, so infections can present atypically and late.
• uncommonNeutropenia— Requires regular neutrophil counts, particularly in the first months.
• uncommonElevated liver enzymes— Especially in systemic JIA and Still's disease.
• rareHypersensitivity reaction— Anaphylaxis has been reported.

• Active serious infection, including untreated latent tuberculosis.
• Neutropenia (absolute neutrophil count below 1.5 x 10^9/L) at baseline.
• Known hypersensitivity to E. coli-derived proteins.
• Concurrent TNF inhibitors - the combination sharply increases serious infection risk without added benefit.

• conflictTNF inhibitors (etanercept, adalimumab) — Combination trials showed higher serious infection and neutropenia rates with no efficacy gain. Do not combine.
• conflictLive vaccines — Avoid during treatment.
• synergyMethotrexate — The standard RA background combination in the pivotal trials.

• · Neutrophil count before starting, monthly for three months, then quarterly for a year.
• · Latent tuberculosis screening before initiation.
• · Liver enzymes in systemic inflammatory disease.
• · Any fever or infection symptom warrants prompt assessment because IL-1 blockade masks the usual signs.

FDA and EMA approved, prescription only.

• Kineret (anakinra) US prescribing information (label)
• Randomised controlled trials of anakinra in rheumatoid arthritis (trial)
• Anakinra in cryopyrin-associated periodic syndromes and Still's disease, clinical reviews (review)

Anakinra is the cleanest example in this entire dataset of a pure competitive receptor block, and the elegance is worth spelling out. IL-1 signalling requires a ternary complex: IL-1 binds IL-1 receptor type 1, and then the IL-1 receptor accessory protein (IL-1RAcP) is recruited to form the signalling complex that engages MyD88 and drives NF-kB and MAP kinase activation. Anakinra binds IL-1R1 with affinity comparable to IL-1 itself but is structurally incapable of recruiting IL-1RAcP. So the receptor is occupied and dead - no partial agonism, no residual signal. Because the block is at the receptor rather than at a cytokine, it neutralises IL-1 alpha and IL-1 beta simultaneously, which is a meaningful difference from canakinumab, an anti-IL-1 beta antibody that leaves IL-1 alpha untouched. That matters clinically wherever IL-1 alpha contributes, such as in some sterile inflammatory states. The other consequence of the mechanism is a receptor occupancy problem: because it is a competitive antagonist against a cytokine that can be produced in enormous local concentrations, a large molar excess of anakinra is needed, which is part of why the dose is 100 mg daily rather than milligrams. The short half-life then becomes a clinical feature rather than only a nuisance - if a serious infection develops, IL-1 blockade washes out within a day, which is something you emphatically cannot say about canakinumab with its multi-week half-life. That washout property is the reason anakinra is often the IL-1 blocker of choice when the patient is unstable or the diagnosis uncertain.

Injection site reactions affect the majority of users in the first month and are the main reason people stop early. They are red, itchy, sometimes painful welts that usually diminish with continued use, and two things genuinely help: let the syringe warm to room temperature for 30 minutes first, and rotate sites at least 2.5 cm apart. People who inject it straight from the fridge have a much worse first month. The serious risk is infection, and the specific danger is presentation rather than incidence - blocking IL-1 blunts the febrile response, so a significant infection can be well advanced before it looks like one. Any infective symptom on this drug warrants prompt assessment rather than watchful waiting. Neutropenia is uncommon but is the reason for the labelled count schedule. In systemic JIA and Still's disease, rising transaminases with falling platelets and rising ferritin is macrophage activation syndrome, not drug hepatitis, and the distinction is urgent. Anaphylaxis has been reported and E. coli-derived protein hypersensitivity is a genuine contraindication. Finally, expectation setting: in rheumatoid arthritis this drug is modest and there are better options, while in the autoinflammatory syndromes it is close to curative. Someone who reads the CAPS literature and expects that response in seropositive RA is going to be disappointed.

1. 100 mgFrom initiation, adults — 100 mg once daily subcutaneously is a flat dose in adults - there is no ramp and no titration. Let the prefilled syringe reach room temperature for about 30 minutes before injecting; cold injection is the single biggest avoidable cause of the injection site reactions that affect most users in the first month.
2. 100 mgRenal impairment, creatinine clearance below 30 mL/min — Same 100 mg dose, but given every other day rather than daily. This is a frequency reduction, not a dose reduction, and it reflects the 70 percent fall in clearance in severe renal impairment.
3. 400 mgSevere autoinflammatory disease, specialist supervision only — Paediatric and severe autoinflammatory dosing is weight-based at 1-2 mg/kg/day and can be escalated to 4 mg/kg/day, and up to 8 mg/kg/day in macrophage activation syndrome. The 400 mg figure here represents a split total daily dose at the upper end for an adult - doses above 100 mg are split rather than given as one injection. This is not self-directed territory.

• Interleukin-1 receptor type 1 (IL-1R1) — Binds with affinity comparable to IL-1 itself; a competitive antagonist rather than a partial agonist

  Occupies the receptor without permitting recruitment of IL-1 receptor accessory protein, so no MyD88 engagement and no downstream NF-kB or MAP kinase signal. Blocks IL-1 alpha and IL-1 beta simultaneously because the block is at the shared receptor.

• IL-1 alpha signalling — Blocked indirectly via IL-1R1 occupancy

  Relevant in sterile inflammation and cell-death-driven states where IL-1 alpha is released as an alarmin. This is the arm that anti-IL-1-beta antibodies do not cover.

• IL-1 beta signalling (NLRP3 inflammasome output) — Blocked indirectly via IL-1R1 occupancy

  The dominant arm in cryopyrin-associated periodic syndromes, Still's disease, systemic JIA, gout flares and recurrent pericarditis, where inflammasome-driven IL-1 beta is the disease. Response in these conditions is dramatic and fast in a way it is not in rheumatoid arthritis.

• Cohen and colleagues, multicentre double-blind randomised placebo-controlled trial of anakinra with background methotrexate in rheumatoid arthritis Randomised controlled trial · n=506 · 24 weeks · 2004

  ACR20 response at week 24: 38 percent on anakinra versus 22 percent on placebo, p<0.001, on background methotrexate. A real, statistically robust result - and a modest one. This 16 percentage point difference is why anakinra never displaced TNF inhibitors in rheumatoid arthritis.

• Goldbach-Mansky and colleagues, anakinra in neonatal-onset multisystem inflammatory disease (NOMID) Open-label with randomised withdrawal · 2006

  Rapid and near-complete resolution of rash, fever, inflammatory markers and CNS inflammation with IL-1 blockade in NOMID, with relapse on withdrawal. This is the trial that turned anakinra from a mediocre rheumatoid arthritis drug into a transformative one for the autoinflammatory syndromes, and the contrast with the RA result is the single most instructive thing about this compound.

Hours 3-7: peak plasma concentration. Hours 24-48: in cryopyrin-associated periodic syndromes and adult-onset Still's disease, fever and rash can resolve completely within this window. That speed is diagnostic in itself - a dramatic response to IL-1 blockade tells you the disease is IL-1 driven. Days 2-14: CRP and serum amyloid A normalise in the autoinflammatory syndromes. Week 1: the injection site reactions are at their worst. Weeks 4-8: injection site reactions typically settle. Weeks 12-24: rheumatoid arthritis response develops slowly and modestly; the pivotal trial measured ACR20 at week 24. Within 24 hours of stopping: the block is essentially gone. That washout is a genuine safety feature, not a limitation.

One combination is genuinely forbidden: TNF inhibitors. Trials of anakinra with etanercept produced higher rates of serious infection and neutropenia with no efficacy gain, and this is a labelled contraindication rather than a theoretical concern. Live vaccines are out during treatment. Methotrexate is the intended background in rheumatoid arthritis and was the comparator backbone in the pivotal trial. The absence of CYP450 metabolism means anakinra is remarkably free of the pharmacokinetic interaction problems that dominate cyclosporine and voclosporin - it does not move levels of anything and nothing moves its level except kidney function. Within this class, combining anakinra with any thymic peptide or immunostimulant is pharmacologically opposed. The comparison worth making rather than the stack is against the other IL-1 blockers: canakinumab and rilonacept have far longer half-lives and much less frequent dosing, but you cannot switch them off, which is why anakinra remains the choice when the patient is septic-looking or the diagnosis is unsettled.

Anakinra is the narrowest and most precise drug in this class - one receptor, one pathway, complete block, out of the system in a day. Compare that against cyclosporine, which blocks a transcription factor upstream of an entire cytokine programme and accumulates. Precision cuts both ways: anakinra causes no nephrotoxicity, no hypertension, no CYP interactions and no myelosuppression beyond occasional neutropenia, and it is also useless in any condition where IL-1 is not the driver. That is the whole story of its rheumatoid arthritis performance. Against canakinumab and rilonacept, anakinra doses daily instead of monthly and blocks IL-1 alpha as well as IL-1 beta, and it can be stopped instantly - which is why it is preferred in unstable patients and in macrophage activation syndrome. Against the thymic peptides in this class it is a different universe of evidence: FDA approved since 2001, two decades of registry safety data, and a well-defined efficacy gradient across indications. It also demonstrates something the rest of this dataset should be read against - a drug with genuinely modest efficacy in its lead indication that was still approved, because modest and measured beats dramatic and unmeasured.

Deliberately null. Kineret is a branded biologic with no biosimilar in most markets and real cost is dominated by insurance coverage, orphan-indication pathways and territory. No verified pricing was resolved in this session.

• ?Volume of distribution is not specified in the FDA label and no reliable independent figure was resolved, so it is null.
• ?Protein binding is not stated on the label and is left null.
• ?Blood-brain barrier penetration is marked partial rather than no: the NOMID trial showed improvement in CNS inflammation, which implies meaningful CNS exposure for a 17 kDa protein, but the extent and mechanism of that penetration are not well characterised and may reflect a disrupted barrier in active disease.
• ?The participant number and duration for the Goldbach-Mansky NOMID study were not confirmed from an accessible abstract and are left null.
• ?The 153-residue sequence is well established and available from primary sources, but was not transcribed or verified residue by residue in this session, so the sequence verified flag is false.
• ?Time to steady state is estimated at about two days from the 4-6 hour half-life with daily dosing; the label does not state it directly.
• ?Optimal dosing in macrophage activation syndrome and in COVID-19 hyperinflammation is not settled - doses up to 8 mg/kg/day appear in the literature but are not labelled.

• KINERET (anakinra) injection - US prescribing information Swedish Orphan Biovitrum, FDA approved product labeling (accessed via openFDA)

  Source of the pharmacokinetics and the monitoring schedule quoted here: 95 percent absolute subcutaneous bioavailability, tmax 3-7 hours, terminal half-life 4-6 hours (median 5.7 in NOMID, range 3.1-28.2), renal clearance with 16/50/70/75 percent reductions across mild to end-stage renal impairment, under 2.5 percent removal by dialysis, and the neutrophil monitoring schedule of baseline, monthly for three months, then quarterly for up to one year.

• A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate Cohen SB, Moreland LW, Cush JJ, et al., Annals of the Rheumatic Diseases, 2004 · PMID 15082469

  The rheumatoid arthritis evidence: 506 patients, ACR20 38 versus 22 percent at 24 weeks. Real but modest, and the honest reason anakinra is a second-line choice in RA.

• Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition Goldbach-Mansky R, Dailey NJ, Canna SW, et al., New England Journal of Medicine, 2006 · PMID 16899778

  The paper that established IL-1 blockade as close to curative in the cryopyrin-associated periodic syndromes. Read alongside the Cohen RA trial to understand how much the indication matters.

• Anakinra - An Interleukin-1 Receptor Antagonist for COVID-19 Nguyen T, et al., American Journal of Therapeutics, 2023 · PMID 36811898

  Review of the hyperinflammation use case, which is where most of the recent interest in short-course anakinra has been.